Neurofilaments as biomarkers in neurological disorders
Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …
number of neurological conditions compared with healthy controls (HC) and is a candidate …
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Objective Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the
cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood …
cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood …
Treatment of multiple sclerosis—success from bench to bedside
M Tintore, A Vidal-Jordana… - Nature Reviews …, 2019 - nature.com
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - Springer
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial …
R Kapoor, PR Ho, N Campbell, I Chang… - The Lancet …, 2018 - thelancet.com
Background Although several disease-modifying treatments are available for relapsing
multiple sclerosis, treatment effects have been more modest in progressive multiple …
multiple sclerosis, treatment effects have been more modest in progressive multiple …
Role of the CXCL13/CXCR5 axis in autoimmune diseases
Z Pan, T Zhu, Y Liu, N Zhang - Frontiers in Immunology, 2022 - frontiersin.org
CXCL13 is a B-cell chemokine produced mainly by mesenchymal lymphoid tissue organizer
cells, follicular dendritic cells, and human T follicular helper cells. By binding to its receptor …
cells, follicular dendritic cells, and human T follicular helper cells. By binding to its receptor …
Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson's disease: roads to biomarker discovery
Parkinson's Disease (PD) is a highly prevalent neurodegenerative disease among older
adults. PD neuropathology is marked by the progressive loss of the dopaminergic neurons …
adults. PD neuropathology is marked by the progressive loss of the dopaminergic neurons …
The evolution of neurofilament light chain in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune, inflammatory neurodegenerative disease of the
central nervous system characterized by demyelination and axonal damage. Diagnosis and …
central nervous system characterized by demyelination and axonal damage. Diagnosis and …
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Background/objectives: Neurofilament light chain (NfL) levels in the cerebrospinal fluid
(CSF) of multiple sclerosis (MS) patients correlate with the degree of neuronal injury. To …
(CSF) of multiple sclerosis (MS) patients correlate with the degree of neuronal injury. To …